This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Cheryl K. McDonald, MD; Daniel R. Kuritzkes, MD

Arch Intern Med. 1997;157(9):951-959.

Abstract
Until recently, treatment for human immunodeficiency virus type 1 (HIV-1) infection was limited to the use of nucleoside inhibitors of the viral enzyme reverse transcriptase. While these agents initially offered promise, they have only modest antiviral activity and the benefits of treatment are limited by the emergence of drug resistance and dose-limiting toxic effects.^1,2 Development of more potent drugs that target different stages of the virus life cycle has thus been aggressively pursued. Efforts to develop inhibitors of HIV-1 protease have yielded a potent new class of compounds that suppress HIV-1 replication to an extent far greater than was previously attainable. Four protease inhibitors, saquinavir mesylate, ritonavir, nelfinavir, and indinavir sulfate, have been approved by the Food and Drug Administration. Other agents are undergoing active investigation. The purpose of this article is to review the currently available data on those agents that have been approved for clinical use.

Arch Intern Med. 1997;157:951-959

Author Affiliations
From the Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-p1 Cleavage Site with a V82A Drug-Resistant Mutation in Viral Protease
Prabu-Jeyabalan et al.
J. Virol. 2004;78:12446-12454.
ABSTRACT | FULL TEXT  

Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy
Prabu-Jeyabalan et al.
J. Virol. 2002;77:1306-1315.
ABSTRACT | FULL TEXT  

Incidence and risk factors for the development of indinavir-associated renal complications
Herman et al.
J Antimicrob Chemother 2001;48:355-360.
ABSTRACT | FULL TEXT  

In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure
La Seta Catamancio et al.
J. Clin. Microbiol. 2001;39:1124-1129.
ABSTRACT | FULL TEXT  

Sources Influencing Patients in Their HIV Medication Decisions
Meredith et al.
Health Educ Behav 2001;28:40-50.
ABSTRACT  

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
Gong et al.
Antimicrob. Agents Chemother. 2000;44:2319-2326.
ABSTRACT | FULL TEXT  

A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical Trial
Jackson et al.
Antimicrob. Agents Chemother. 2000;44:1832-1837.
ABSTRACT | FULL TEXT  

Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease
Lin et al.
J. Virol. 2000;74:4710-4720.
ABSTRACT | FULL TEXT  

Interactions of HIV Protease Inhibitors with a Human Organic Cation Transporter in a Mammalian Expression System
Zhang et al.
Drug Metab. Dispos. 2000;28:329-334.
ABSTRACT | FULL TEXT  

Life-Threatening Interactions Between HIV-1 Protease Inhibitors and the Illicit Drugs MDMA and {gamma}-Hydroxybutyrate
Harrington et al.
Arch Intern Med 1999;159:2221-2224.
ABSTRACT | FULL TEXT  

Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1
Kashuba et al.
Antimicrob. Agents Chemother. 1999;43:1817-1826.
FULL TEXT  

Protease Inhibitors as Antiviral Agents
Patick and Potts
Clin. Microbiol. Rev. 1998;11:614-627.
ABSTRACT | FULL TEXT  

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir
Patick et al.
Antimicrob. Agents Chemother. 1998;42:2637-2644.
ABSTRACT | FULL TEXT  

Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors
Hecht et al.
NEJM 1998;339:307-311.
FULL TEXT  

Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment
Winters et al.
J. Virol. 1998;72:5303-5306.
ABSTRACT | FULL TEXT  

Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro
Harrigan et al.
J. Virol. 1998;72:3773-3778.
ABSTRACT | FULL TEXT  

Improvement in CD4+ Cell Counts despite Persistently Detectable HIV Load
Levitz
NEJM 1998;338:1074-1075.
FULL TEXT  

A genetic screen for the isolation and characterization of site-specific proteases
Sices and Kristie
Proc. Natl. Acad. Sci. USA 1998;95:2828-2833.
ABSTRACT | FULL TEXT